|
|
|
Insider
Information: |
Klencke Barbara |
Relationship: |
Director |
City: |
Vancouver |
State: |
A1 |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
50,986 |
|
Indirect Shares
|
25,000 |
|
|
Direct
Value |
$125,826 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
75,986 |
|
|
Total
Value |
$125,826 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Sierra Oncology Inc |
SRRA |
Chief Medical Officer |
2022-07-01 |
0 |
2022-07-01 |
0 |
Premium* |
|
Tscan Therapeutics, Inc. |
TCRX |
|
2024-09-23 |
45,000 |
2024-09-23 |
25,000 |
Premium* |
|
Xencor Inc |
XNCR |
Director |
2024-06-13 |
5,986 |
2024-06-13 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
14 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SRRA |
Sierra Oncology Inc |
Chief Medical Officer |
|
2022-07-01 |
4 |
D |
$55.00 |
$550,000 |
D/D |
(10,000) |
0 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Medical Officer |
|
2022-07-01 |
4 |
D |
$55.00 |
$275,000 |
I/I |
(5,000) |
0 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Development Officer |
|
2020-08-18 |
4 |
B |
$12.25 |
$40,738 |
I/I |
3,325 |
5,000 |
1.99 |
- |
|
XNCR |
Xencor Inc |
Director |
|
2024-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
5,986 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Development Officer |
|
2020-08-18 |
4 |
B |
$12.22 |
$72,710 |
D/D |
5,950 |
10,000 |
2.74 |
- |
|
TCRX |
Tscan Therapeutics, Inc. |
Director |
|
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,000 |
|
- |
|
TCRX |
Tscan Therapeutics, Inc. |
Director |
|
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
TCRX |
Tscan Therapeutics, Inc. |
|
|
2023-12-14 |
4 |
B |
$5.08 |
$25,400 |
D/D |
5,000 |
30,000 |
0.01 |
- |
|
TCRX |
Tscan Therapeutics, Inc. |
|
|
2024-08-23 |
4 |
B |
$5.69 |
$28,450 |
D/D |
5,000 |
35,000 |
0.01 |
- |
|
TCRX |
Tscan Therapeutics, Inc. |
|
|
2024-08-26 |
4 |
B |
$5.53 |
$27,650 |
D/D |
5,000 |
40,000 |
0.01 |
- |
|
TCRX |
Tscan Therapeutics, Inc. |
|
|
2024-09-23 |
4 |
B |
$5.29 |
$26,450 |
D/D |
5,000 |
45,000 |
0.01 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Development Officer |
|
2019-08-22 |
4 |
B |
$0.45 |
$24,295 |
D/D |
54,000 |
54,000 |
2.74 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Development Officer |
|
2019-08-22 |
4 |
B |
$0.43 |
$28,964 |
I/I |
67,000 |
67,000 |
1.99 |
- |
|
SRRA |
Sierra Oncology Inc |
Chief Development Officer |
|
2019-08-23 |
4 |
B |
$0.44 |
$47,380 |
D/D |
108,000 |
162,000 |
2.74 |
- |
|
14 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|